Cancer Research Month: SBRT Shows Effectiveness for Early-Stage Lung Cancer

The American Association for Cancer Research acknowledges May as National Cancer Research Month to recognize high-quality, innovative cancer research and make it a top priority. Through various studies, researchers are able to identify cancer risk factors and evaluate optimal treatment options for cancer patients.

One recent study revealed excellent long-term, local control rates for medically inoperable, early stage lung cancer patients treated with stereotactic body radiation therapy (SBRT). From 2003 to 2012, 300 patients with a total of 340 lesions were treated with SBRT.

According to the 10 years of data collected, the results revealed excellent, sustained local control with minimal side effects for medically inoperable, early stage lung cancer patients who received high-dose rate stereotactic body radiotherapy (SBRT).

The results provide significant evidence and support for SBRT as a viable treatment option for early-stage lung cancer.

To learn more about this study and read the full results, click here.

Austin CyberKnife treats primary, recurrent and metastatic lung tumors with SBRT using CyberKnife® technology. To learn more about our treatment process, click here.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.